相关实验视频
Updated: Jun 6, 2025

Enhancing Tumor Content through Tumor Macrodissection
Published on: February 12, 2022
分散大B细胞淋巴瘤的分子特征与初级治疗耐药性相关
Allison M Bock1,2, Kerstin Wenzl3, Joseph P Novak1
1Division of Hematology, Mayo Clinic Rochester, Rochester, Minnesota, USA.
基因组分析显示TP53和ARID1A突变在扩散性大B细胞淋巴瘤 (DLBCL) 患者中更常见,这些患者具有初级治疗耐药性 (PTR). 一个新的签名在诊断时识别这些高风险的PTR病例.
科学领域:
- 在瘤学瘤学.
- 遗传学 是一个遗传学.
- 分子生物学分子生物学
背景情况:
- 扩散性大B细胞淋巴瘤 (DLBCL) 患者在初始治疗中未达到完全反应时,面临着糟糕的结果.
- 了解分子驱动因素对于识别治疗耐药性至关重要.
- 目前的分子分类器无法充分预测DLBCL中的初级治疗耐药性 (PTR).
研究的目的:
- 调查DLBCL的基因组景观,主要治疗耐药性 (PTR).
- 将PTR DLBCL的基因组资料与非PTR DLBCL进行比较.
- 评估当前分子分类器的有效性,并开发用于PTR预测的新型特征.
主要方法:
- 新诊断的DLBCL患者样本的整体外体和RNA测序.
- 在PTR和非PTRDLBCL队列之间进行比较基因组分析.
- 路径分析以确定失调的分子机制.
主要成果:
- 在PTR病例中,TP53突变显著增加 (34%对15%).
- 在PTR病例中,ARID1A突变也显著升高 (21%与7%相比).
- 途径分析表明TP53下调和增加了PTR DLBCL中的染色体修饰活性.
- 一个新开发的高风险签名在诊断时识别了46%的PTR病例,超过了现有的分类器.
结论:
- TP53和ARID1A突变是DLBCL中初级治疗耐药性的关键媒介.
- 这些遗传变化和相关途径导致治疗结果不佳.
- 一种新的基因组签名可以在诊断时识别具有PTR的高风险DLBCL患者,从而实现潜在的治疗分层.
更多相关视频
14:51Pooled shRNA Library Screening to Identify Factors that Modulate a Drug Resistance Phenotype
Published on: June 17, 2022
08:46Implementation of In Vitro Drug Resistance Assays: Maximizing the Potential for Uncovering Clinically Relevant Resistance Mechanisms
Published on: December 9, 2015
相关概念视频
Treatment Resistant Cancers
Targeted Cancer Therapies
There are several types of targeted therapies against...
Special Features of Adaptive Immunity
The primary cell types involved in adaptive immunity are T cells and B cells. Each type has a unique role in defending the body against pathogens. T cells are responsible for cell-mediated immunity. They identify and eliminate infected cells directly,...
B Cell Activation and Differentiation
When naive B cells encounter a specific antigen that can bind to the B cell receptor (BCR) on their surface, they undergo sensitization to respond to the antigen's presence. Sensitization begins with...
Combination Therapies and Personalized Medicine
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...